Greenwich LifeSciences, Inc. reports developments as a clinical-stage biopharmaceutical company focused on FLAMINGO-01, a Phase III clinical trial evaluating GLSI-100 as an immunotherapy intended to prevent breast cancer recurrences. GLSI-100 combines the GP2 peptide with GM-CSF and is described by the company as a Fast Track designated program.
Recurring news includes FLAMINGO-01 clinical-site activity, oncology conference abstracts and posters, open-label immune-response and recurrence-rate data, patent-claim updates tied to GP2, at-the-market equity financing activity, and SEC reporting or Nasdaq compliance matters related to periodic filings.
Greenwich LifeSciences announced the closing of its initial public offering, selling 1,260,870 shares at $5.75 each, totaling $7,250,002 in gross proceeds. The offering includes a 45-day option for the underwriter to purchase an additional 189,130 shares. Trading commenced on Nasdaq under the symbol 'GLSI' on September 25, 2020. The company focuses on developing GP2, an immunotherapy aimed at preventing breast cancer recurrence in patients post-surgery. The Phase IIb trial results showed no recurrences after five years in the treated group, highlighting positive clinical outcomes.